JAMA. 1976 Sep 6;236(10):1131-5. doi: 10.1001/jama.1976.03270110029022.
Bone marrow transplantation from HLA-matched allogeneic donors was used to treat two series of patients with severe aplastic anemia. No significant differences were detected in all comparisons made between the Registry series (38 patients) and the Seattle series (24 patients), and pooled data from the two series were used in the analyses. Currently, 55% of the patients who received bone marrow transplants within three months of diagnosis are alive, but only 13% of the patients who received bone marrow transplants more than nine months after diagnosis are alive. The difference between the two groups was significant (P less than .02). Patients less than 21 years of age had a significantly higher survival rate than those patients who were 21 years or older at the time of transplantation (P less than .02). Survival rates were significantly higher for patients who had received 15 or fewer pretransplant transfusions than those who received more (P less than .05).
采用来自人类白细胞抗原（HLA）匹配的同种异体供者的骨髓移植来治疗两组严重再生障碍性贫血患者。在登记处系列（38例患者）和西雅图系列（24例患者）之间进行的所有比较中，未检测到显著差异，分析中使用了来自这两个系列的汇总数据。目前，在诊断后三个月内接受骨髓移植的患者中，55%仍然存活，但在诊断后九个月以上接受骨髓移植的患者中，只有13%仍然存活。两组之间的差异具有显著性（P小于0.02）。年龄小于21岁的患者的存活率显著高于移植时年龄在21岁及以上的患者（P小于0.02）。移植前接受15次或更少输血的患者的存活率显著高于接受更多输血的患者（P小于0.05）。
